Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 9Unknown 6Recruiting 5Terminated 2Not yet recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 83Carcinoma, Non-Small-Cell Lung 79Breast Neoplasms 71Leukemia, Myeloid, Acute 39Colorectal Neoplasms 37Recurrence 36Prostatic Neoplasms 34Neoplasm Metastasis 30Multiple Myeloma 28Lymphoma 26Pancreatic Neoplasms 25Melanoma 25Lymphoma, Non-Hodgkin 24Lung Neoplasms 24Leukemia, Lymphocytic, Chronic, B-Cell 23Ovarian Neoplasms 22Lymphoma, Follicular 22Carcinoma, Hepatocellular 22Carcinoma, Renal Cell 21Stomach Neoplasms 19Squamous Cell Carcinoma of Head and Neck 19Lymphoma, Large B-Cell, Diffuse 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Myelodysplastic Syndromes 18Leukemia 18Head and Neck Neoplasms 18Urinary Bladder Neoplasms 17Hematologic Neoplasms 14Carcinoma 13Uterine Cervical Neoplasms 12

Interventions

1-(4-(4-(3-oxa-8-azabicyclo(3.2.1)octan-8-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × INDUSTRY × Advanced Malignant Solid Tumors × Clear all
NCT00997360 2018-09-27

Study of PKI-179 Administered Orally to Subjects With Solid Tumors

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 1 Withdrawn
Other solid neoplasm

Advanced Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡